Closed to Enrollment
A5332 Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE.
A5357 A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living with HIV-1.
A5359 The LATITUDE Study. Long-Acting Therapy to Improve Treatment SUccess in Daily LifE. A Phase III Study to Evaluate Long-Acting Antiretroviral Therapy in Non-Adherent HIV-Infected Individuals.
A5366 Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors.
A5377 A Phase I, First-in-Human Study of SAR441236, a Tri-specific Broadly Neutralizing Antibody, in Participants with HIV.
A5379 B-Enhancement of HBV Vaccination in Persons Living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B.
A5383 Randomized, Controlled Trial to Evaluate the Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults with Human Immunodeficiency Virus (HIC)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes (ELICIT).
A5391 Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT study).
A5407 A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared with Placebo in Non-Hospitalized Participants with COVID-19.
CD4 A Pilot Study of T Cells Genetically Modified by Zinc Finger Nucleases and CD4 Chimeric Antigen Receptor in HIV-infected Subjects
SARS-CoV-2Dmab01: (DARPA) A Phase 1, Open-Label, Single Center, Dose Escalation Study of the Safety and Pharmacokinetics of MAB AZD5396 and MAB AZD8076 Delivered as DMABS in Healthy Adults.
Gilead 6041 Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination with Lenacapavir in Virologically Suppressed People with HIV.
Merck 20 A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment-Naive Participants.
Merck 33 A Phase 3 Open-Label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study.
Merck 51 A Phase 3, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in Participants With HIV-1 Who are Virologically Suppressed on Antiretroviral Therapy.
Merck 54 A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL (100 mg/0.75 mg) QD in a Phase 3 Clinical Study.
Define A Phase 4, Randomized, Active-Controlled, Open-Label Study to Evaluate the Safety and Tolerability of Switching to Once-Daily Darunavir/Cobicistat/Emitricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Regimen in Virologically-Suppressed Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Experiencing Rapid Weight Gain with an INI + TACF/FTC ARV Regimen.
AZ- D7000C00001: (SUPERNOVA) A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment. Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA).
A5386 A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist( N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption.
MCA-1031 (Rockefeller 2) An open label, single arm study of the safety and antiretroviral activity of the combination of two long-acting broadly neutralizing antibodies plus an IL-15 superagonist complex in ART-treated adults living with HIV during analytical treatment interruption.
ViiV - Embrace A Phase 2b Multicenter, Randomized, Open-Label Study Comparing the Efficacy, Safety, PK, and Tolerability of VH3810109, Administered Either Intravenously Or As A Subcutaneous Infusion with rHuPH20, in Combination with CAB LA to
Standard of Care in Virologically Suppressed Adults Living with HIV.
ViiV – Eyewitness A Phase 3b, multicenter, single-arm, open-label study evaluating the efficacy, safety, and tolerability of switching to DTG/3TC single tablet regimen administered once daily from a bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen in people living with HIV of at least 50 years of age who are virologically suppressed.
Knowledge, perception and practice of breastfeeding among women living with HIV in Philadelphia.
A5418 A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease.
A5355 Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based anti-Cytomegalovirus (CMV) Vaccine (Triplex®), in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART with Conserved Immune Function.
Knowledge, perception and practice of breastfeeding among women living with HIV in Philadelphia.